

Complete genomic characterization and genetic diversity of four European genotype porcine reproductive and respiratory syndrome virus isolates from China in 2011

Zhi Zhou¹ · Qi Liu¹ · Dongmei Hu¹ · Qian Zhang¹ · Tao Han¹ · Ying Ma¹ · Xiaoxue Gu¹ · Xinyan Zhai¹ · Kegong Tian^{1,2}

Received: 16 July 2015/Accepted: 23 October 2015/Published online: 14 November 2015 © Springer Science+Business Media New York 2015

Abstract Porcine reproductive and respiratory syndrome (PRRS) is an emerging disease that has caused serious economic losses to the swine industry worldwide. In 2011, a nation-wide surveillance program investigated the prevalence of PRRS viruses (PRRSV) in Chinese breeding swine farms, and four European genotype PRRSV (PRRSV-Type 1) were successfully isolated. To explore the genetic diversity of PRRSV-Type 1 in China, these 4 viral strains were subjected to genome sequencing and analysis. The four isolates shared 87.4-90.7 % nucleotide homology with the Lelystad strain (PRRSV-Type 1 stereotype strain). NSP2, ORF3, and ORF4 were the most variable regions and contained discontinuous deletions or insertions when compared to other PRRSV-Type 1 strains. All isolates fell into separate branches of the subtype 1 of PRRSV-Type 1 phylogenetic tree. This analysis of emerging PRRSV-Type 1 strains revealed previously

Edited by William Dundon.

Zhi Zhou and Qi Liu are contributed equally to this study.

Electronic supplementary material The online version of this article (doi:10.1007/s11262-015-1256-z) contains supplementary material, which is available to authorized users.

Xinyan Zhai Zhaixy2010@sina.cn

Kegong Tian tiankg@263.net

¹ OIE Porcine Reproductive and Respiratory Syndrome Reference Laboratory, China Animal Disease Control Center, No. 20 Maizidian Road, Chaoyang District, Beijing 100125, China

² National Research Center for Veterinary Medicine, Cuiwei Road, High-Tech. District, Luoyang, Henan, China unrecorded genetic diversity. Close attention should be paid to the prevention and control of this evolving virus.

Keywords PRRSV-Type 1 · Chinese swine herds · Genetic variation

Introduction

Porcine reproductive and respiratory syndrome (PRRS) is one of the most important swine infectious diseases and causes great economic losses in the swine industry worldwide [1, 2]. PRRS virus (PRRSV) is a member of the Arterivirus genus, family Arteriviridae, order Nidovirales, and is a small enveloped virus with a single-stranded positive-sense RNA genome [3]. The genome of PRRSV is approximately 15 kb and contains at least ten overlapping open reading frames (ORFs), including ORF1a, ORF1b, ORF2a, ORF2b, ORF3, ORF4, ORF5a, ORF5, ORF6, and ORF7 [4-6]. Of these, ORF1a and ORF1b are located at the 5' terminal of the genome and encode viral nonstructural proteins (Nsp), while ORFs2-7 are located at the 3'terminal region of the genome, and encode minor structural proteins (GP2, GP3, and GP4) and major structural proteins(GP5a, GP5, M, and N) [2, 4, 7].

PRRSV genome sequences are highly diverse and can be divided into European genotype (PRRSV-Type 1) and North American genotype (PRRSV-Type 2) [8, 9]. PRRSV-Type 1 first emerged in Europe, and the Lelystad virus represents the prototypical Type 1 strain [1]. PRRSV-Type 2 emerged in North America, and the ATCC VR-2332 strain represents the prototype Type 2 virus [10]. Originally, PRRSV-Type 1 viruses were only detected in European swine herds. However, PRRSV-Type 1 has recently been reported in North America and Asian swine herds, and the coexistence of these two genotypes in swine herds represents a huge challenge for PRRSV differential diagnosis, and disease prevention and control [11–16].

In China, the emergence of the PRRSV-Type 1 strains has been previously reported [17], but most PRRSV isolates have been of the PRRSV-Type 2 genotype, and the origin and molecular evolution of PRRSV-Type 1 in China is currently unknown. To gain further insight into the epidemic status and genetic divergence of PRRSV-Type 1 viruses in China, 4 PRRSV-Type 1 viruses were isolated in 2011, and subjected to genomic analysis.

Materials and methods

Ethics statement

The 4136 marginal ear vein blood samples were collected from 80 breeding swine farms in China. Since this study was carried out in private farms, the animals were sampled with the permission of the farm managers. The animal field trial was approved by the Animal Care and Ethics Committee of China Animal Disease Control Center and conventional animal welfare regulations and standards were adhered to.

Virus isolation

The serum samples were screened for both PRRSV genotypes by conventional RT-PCR [12]. Samples that tested positive for PRRSV were screened by a real-time RT-PCR for PRRSV-Type 1 and PRRSV-Type 2 [18]. PRRSV-Type 1 positive serum samples were inoculated on primary porcine alveolar macrophages (PAMs) and Marc-145 cells for virus isolation as previously described [19, 20]. Inoculated cells were maintained at 37 °C in a 5 % CO₂ atmosphere and were monitored daily for cytopathic effects (CPE). When CPE were observed in 70 % of the cells, cultures were harvested and the resultant virus stocks were stored at -80 °C.

RNA extraction and genome sequencing

Total RNA was extracted from cell cultures using an RNeasy Mini kit (Qiagen, Germany) according to the manufacturer's instructions. Whole genomes were sequenced as previously described [17]. Briefly, 16 overlapping fragments covering the whole viral genome were amplified by RT-PCR using the corresponding primers. PCR products were purified with E.Z.N.A.TM Gel Extraction Kit (Omega, USA) and were cloned into pEASY-T1 (Transgen, China). The recombinant plasmids were sequenced with an ABI Automatic DNA Sequencer (Invitrogen, China) and artificially spliced. Gene fragments were sequenced in triplicate and were assembled with ContigExpress in NTI Advance 11Vector [21].

Multiple sequence alignments and phylogenetic analysis

Multiple alignments were performed for each ORF separately using all available PRRSV-Type 1 virus whole genome sequences in GenBank (Suppl. Table). Phylogenetic trees were constructed from aligned nucleotide sequences using the neighbor-joining method, and were subsequently subjected to bootstrap analysis with 1000 replicates to determine the percentage of reliabilities at each internal node of the tree. The tree was produced using the MEGA4.1 program [22].

Results

Four PRRSV-Type 1 viruses were isolated in a national epidemiological survey

To explore the prevalence of PRRSV-Type 1 virus infection in Chinese swine herds, 4136 serum samples were collected from 80 breeding swine farms in different provinces. All samples were subjected to conventional RT-PCR for both genotypes of PRRSV, and samples in which PRRSV was detected underwent real-time RT-PCR for PRRSV-Type 1 and PRRSV-Type 2 differentiation [12, 18]. PRRSV-Type 2 virus was detected in 18/80(22.5 %) breeding swine farms and PRRSV-Type 1 virus was detected in 8/80(10 %) farms in China. The PRRSV-Type 1 virus-positive serum samples were subsequently inoculated on primary PAM and Marc-145 cells. After 3 days, four inoculates exhibited a cytotoxic effect on PAMs but not on Marc-145 cells. Moreover, these isolates were labeled by PRRSV-specific monoclonal antibodies, further confirming the presence of PRRSV, and excluding contamination with other swine viruses (data not show). These 4 PRRSV isolates were designated NVDC-NM1-2011, NVDC-NM2, NVDC-NM3, and NVDC-FJ.

Genomic sequence analysis of 4 PRRSV-Type 1 isolates

The complete genomic sequences of four viral isolates were assembled into contiguous sequences of 15081(NVDC-NM1-2011, GenBank accession no.JX187609), 15061 (NVDC-NM2, GenBank accession no.KC492504), 15058(NVDC-NM3, GenBank accession no.KC492505), and 15058(NVDC-FJ, GenBank accession no.KC492506) nucleotides(nt) in length excluding the 3' poly(A) tails. The

complete genome nucleotide homology of these four isolates was 85.6-95.5 %. They also shared 87.4-90.7 % nt homology with Lelystad PRRSV (the PRRSV-Type 1 reference strain), 86.9-88.8 % with the PRRSV-Type 1 live-attenuated vaccine, 72.3-78.5 % with Lena PRRSV (highly pathogenic PRRSV-Type 1 strain), and 53.2-54.5 % with VR-2332 PRRSV (the PRRSV-Type 2 prototype strain). In comparison to the genomic sequences of another two Chinese PRRSV-Type 1 isolates BJEU06-1 and NMEU09-1, these isolates shared 86.5-93.7 % homology with BJEU06-1 and 84.3-87.6 % homology with NMEU09-1. To further explore the genetic variety of these four isolates, the sequence of NVDC-NM1-2011 was compared to that of NVDC-NM2, NVDC-NM3, NVDC-FJ, LV, BJEU06-1, NMEU09-1, EuroPRRS, 01CB1, SD01-08, KNU-07, HKEU16, and Lena PRRSV (Table 1).

5'-UTR and 3'-UTR sequence variations of 4 PRRSV-Type 1 isolates

The 5' terminus of the PRRSV genome contains a conserved start motif and the UUAACC transcription regulatory sequence (TRS) which are involved in transcription and replication [23–25]. In this study, the 5'-UTR region of all four isolates was 221 nucleotides in length. Moreover, the 12-nt 5'-leader start motif and the leader TRS were strictly conserved in the 5'-UTR of 4 PRRSV-Type 1 isolates (Fig. 1a). The 5'-UTR region of LV and VR-2332 strains were previously shown to contain three invariant nucleotide stretches just upstream of the leader TRS [24]. As expected, the nucleotide sequences of the three invariant motifs (Fig. 1a, solid boxes) were well maintained in NVDC-NM2, NVDC-NM3, and NVDC-FJ isolates.

Table 1 Detailed analysis of the complete genome for NVDC-NM1-2011 with 3 isolates in 2011 and other representative strains (%)

NVDC-	NVDC-	NVDC-	NVDC-	LV	% Identity	to NVDC-N	M1-2011		SD01-	KNU-	HKEU16	Lena	VR-
NM1-2011	NM2	NM3	FJ		BJEU06- 1	NMEU09- 1	EuroPRRSV	01CB1	08	07			2332
Nucleotides													
Complete	85.6	85.8	85.9	90.7	93.7	84.3	88.7	89.8	88.2	86.2	86.4	78.5	54.5
5'UTR	95.0	95.0	95.0	97.2	97.6	95.3	91.0	n/a	95.8	94.8	94.8	90.1	42.2
ORF1a	85.2	85.2	85.3	89.8	93.9	81.4	87.5	89.7	86.8	83.5	85.0	75.1	50.1
ORF1b	85.7	85.7	85.7	92.4	95.2	86.6	90.6	92.4	89.7	88.5	88.5	81.4	62.2
ORF2-7	86.9	87.1	87.5	91.2	91.7	87.2	89.9	91.1	90.1	88.4	87.4	84.2	65.0
3'UTR	89.5	93.0	93.0	95.6	95.6	95.6	93.9	n/a	95.6	93.9	93.9	89.5	74.3
Amino acid													
NSP1α	89.6	89.6	89.6	94.5	95.1	93.9	89.6	94.5	92.6	94.5	90.8	90.2	68.1
NSP1β	84.0	84.0	84.0	86.3	100	80.4	81.3	85.4	80.4	79.9	83.1	72.5	44.6
NSP2	83.4	83.6	83.7	85.4	92.5	72.7	82.0	85.4	82.0	79.4	78.6	65.9	30.2
NSP3	91.3	90.8	91.3	94.0	95.5	93.5	92.9	94.4	94.0	91.7	93.3	89.1	58.8
NSP4	84.7	85.1	84.7	90.6	89.6	83.7	91.1	90.1	88.1	88.1	88.1	82.7	58.7
NSP5	89.4	90.0	90.0	95.9	95.9	87.1	95.3	95.3	94.7	91.8	91.2	87.1	67.9
NSP6	100	100	100	100	100	100	100	95.2	95.2	95.2	95.2	90.5	81.3
NSP7	92.4	92.4	92.4	95.4	95.8	91.6	95.4	95.1	94.7	92.8	95.1	87.1	49.8
NSP8	93.3	93.3	93.3	97.8	100	93.3	97.8	97.8	95.6	93.3	91.1	93.3	63.0
NSP9	95.8	96.0	95.8	97.8	99.8	95.8	96.9	97.8	97.8	96.9	96.7	92.6	74.6
NSP10	93.0	92.5	92.5	95.5	96.1	93.7	94.6	95.2	94.3	94.1	91.4	89.5	64.3
NSP11	97.1	97.1	97.1	97.5	98.7	96.2	96.2	97.1	96.7	96.2	95.4	93.8	74.7
NSP12	91.0	91.0	91.0	96.3	94.0	90.3	94.8	95.5	95.5	91.8	91.0	86.6	42.7
ORF2a	88.8	88.8	88.8	94.4	98.0	88.0	92.8	94.0	92.0	89.2	90.0	90.0	62.2
ORF2b	81.9	81.9	81.9	91.7	95.8	80.6	90.3	93.1	88.9	81.9	81.9	81.9	64.4
ORF3	82.1	82.1	82.9	86.4	85.2	83.7	85.2	86.4	86.0	79.5	82.9	79.9	59.4
ORF4	89.7	89.7	90.8	87.4	90.2	86.8	89.0	87.4	89.6	84.1	87.9	86.8	71.3
ORF5a	90.7	90.7	90.7	95.3	93.0	95.3	93.0	90.7	97.7	97.7	93.0	88.4	48.8
ORF5	84.2	84.2	84.2	90.8	91.3	88.3	86.7	89.8	89.3	87.2	89.8	82.1	57.1
ORF6	91.3	91.3	91.9	96.0	92.5	92.5	95.4	94.8	93.6	92.5	90.8	91.3	76.3
ORF7	88.3	89.8	89.8	92.2	91.4	88.3	91.4	91.4	93.0	89.1	86.7	86.3	63.2

Α		
LV		111
NVDC-NM1-2011	AC	111
NVDC-NM2		111
NVDC-NM3		111
NVDC-FJ		111
BJEU06-1		111
NMEU09-1		111
EuroPRRSV		111
SD01-08	C	111
KNU-07	UUG.G.G.ACUUU.	111
HKEU16	ACUG.UU	111
Lena	A	111
12 :	nt start motif site	
LV	ົງວັດໄມ້ນັ້ນຕີກວງຊວງບວນຊອງສອງແບບເວຍເບວງແວຍຊອງຊອອງວນເບັງແອຍອງແອຍອາດຊອອງຊອງຊວຍແບວງບ່າວຍາວອາວອາຍອຍຊອງອອງແບບບາງແບບ	221
NVDC-NM1-2011		221
NVDC-NM2	ccc	221
NVDC-NM3	ccc	221
NVDC-FJ	ccc	221
BJEU06-1	σ.μ	221
NMEU09-1		221
EuroPRRSV	C	221
SD01-08		221
KNU-07	· · · · · · · · · · · · · · · · · · ·	221
HKEU16	с.ссс	221
Lena	c	221
	TRS	
В		
τ.v		π 11
NVDC-NM1-2011	. GU . UG	. 11
NVDC-NM2		. 11
NVDC-NM3		. 11
NVDC-FJ		. 11
BJEU06-1	GU	. 11
NMEU09-1	Ū	. 11
EuroPRRSV	UA.	. 11
SD01-08		. 11
KNU-07	ŪŪ.	. 11
HKEU16	U	. 11
Lena_virus	GA.A.GU.GU.GUCGAU.GU.GU.GU.G	. 11

Fig. 1 Alignment of 5'-UTR (A) and 3'-UTR (B) sequences of PRRSV-Type 1 viruses. **a** The12-nt start motif, leader TRS, and three invariant nucleotide stretches were indicated by a *black box*, a *dotted*

However, in the NVDC-NM1-2011 isolate C was substituted with U in the third stretch, a mutation similar to the 5'-UTR motifs changes observed in the BJEU06-1 isolate. The 3'-UTR of four isolates was 114 nucleotides in length and contained 5 or 9 nucleotide changes (Fig. 1b).

Amino acid alteration in Nsp2 of 4 PRRSV-Type 1 isolates

The highly variable PRRSV protein, Nsp2, is the least conserved viral protein [2, 26]. In this study, several differences were found in the NSP2 as sequence of all four isolates, when compared to the NSP2 sequence of the reference LV strain. Six aa deletions (deletion of 1 aa at residue 277, 4 aa at residue 357–360, and 1 aa at residue 411) were observed within the NSP2 of the NVDC-NM2, NVDC-NM3, and NVDC-FJ isolates, and five discontinuous deletions (4 aa deletions at residue 357–360 and 1 aa deletion at residue 411) were observed in the NVDC-NM1-2011 isolate (Fig. 2). Notably, in four isolates, 1 aa was

line box, and solid boxes, respectively. **b** Alignment of 3'-UTR sequence of PRRSV-Type 1 viruses

deleted at residue 411, located in ES4 as not found in other viruses [27, 28]. In addition, a unique insertion of arginine was found at residue 757 of NVDC-NM2 that was not present in all the other viruses.

Genetic characteristics of structural ORFs of 4 PRRSV-Type 1 isolates

The structural ORF nucleotide sequences (ORFs 2-7) of four isolates shared 91.4 % (NVDC-NM1-2011), 88.5 % (NVDC-NM2), 88.8 % (NVDC-NM3), and 88.7 % (NVDC-FJ) nucleotide homology with LV strain. The amino acid sequences of four isolates shared 83.7–96.1 % identity with the LV strain (Table 2).The structural proteins GP3 and GP5 were next analyzed with other representative PRRSV-Type 1 isolates from China and other countries.

GP3, a minor structural protein contains a hypervariable region (aa 237–252) in the overlap regions of ORF3 and ORF4 in PRRSV-Type 1 viruses [29]. Consistent with

Fig. 2 Alignment of NSP2 amino acid sequences of four isolates with other PRRSV-Type 1 strains. The amino acid discontinuous deletions detected in four isolates were indicated with *solid boxes*. One amino acid insertion at position 757 was indicated with a *dotted line box*. The previously identified B-cell epitope sites (ES) were indicated with *underlining*

120 GITTYSPPTDGSCGWHVLAAIMNRMINGDFTSPLTQYNR<u>PEDDWASDYDLVQA</u>IQCLRLPATV AAGKRARAKRAAKSEKDSAPTPKVALE
 LV
 AAGKRARAKAAKSEKDSAPTPKVALPVPTCGITTYSPFDGSCGMHVLAAINNRMINGDFTSPLTQYNRPEDDNASDYDLVQAIQCLRLPATVVRNRACPNAKYLIKLNGVHKEVEVENS

 NVDC-NN1-2011
 ... R.G. P. A. .. N. .. N. .. V. D. P. A. Q. AI.S. ... V. A.

 NVDC-NN2
 ... R.G. P. A. EAT. T. EVI A. ... M. D. P. Q. V. Q. AI.G. ... TI

 NVDC-NN3
 ... R.G. P. A. EAT. T. EVI A. ... M. D. P. Q. V. Q. AI.G. ... TI

 NVDC-NN3
 ... R.G. P. A. EAT. T. EVI A. ... M.D. P. V. Q. AI.G. ... TI

 NVDC-NN3
 ... R.G. P. A. EAT. T. EVI A. ... M.D. P. V. Q. ... Q. AI.G. ... TI

 NVDC-NN4
 ... R.G. P. A. EAT. T. EVI A. ... M.D. P. V. Q. ... Q. AI.G. ... TI

 NVDC-NN5
 ... R.G. P. A. EAT. T. EVI A. ... M.D. P. V. Q. ... Q. AI.G. ... TI

 NUDC-NN4
 ... R.G. P. A. EAT. T. EVI A. ... M.D. P. V. Q. ... Q. AI.G. ... TI

 BJEU06-1
 ... R.G. P. E. A. VI A. ... M.D. P. A. Q. AI.S. ... V. A.

 NEUD09-1
 ... V. KD. PYV. VQ.S. H. P. G. ... D. ... AR

 MEU09-1
 ... V. KD. PYV. VQ.S. H. P. G. ... D. ... AR

 S001-06
 ... T. ... G. ... A. Q. Q. Q. Q. Q. Q. Q. Q. Q. Q. 121 LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ NVDC-FJ GMAPRSLSRECVVGVCSEGCVAPPYPADGLPKRALEALASAYRLPSDCVSSGIADFLANPPPQEFWILDKMLISPSPERSGFSSLYKLLLEVVPQKCGATEGAFIYAVERMLKDCPSSKQ BJEU06-1 NMEU09-1 EuroPRRSV 01CB1 SD01-08 KNU-07 HKEU16 Lena 411 ES4 48 E CS
 361
 ES4
 411
 ES5
 43

 VGONLSPSDPHKINLINSELDSQAPASTTILVEGYEDNEGDALEVTVREFVPTGFILCHVEHCGTESGDSSPLDSQATLDQENLSLAMEVBATASDPGWVHGREE
 4
 5
 5
 5
 5
 5
 6
 1
 1
 ES5
 4
 5
 1
 5
 5
 5
 5
 6
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
LV NVDC-NM1-2011 NVDC-NM2 NVDC-NM3 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV 010B1 01CB1 SD01-08 KNU-07 HKEU16 Lena 81 ES6 60 PFVFVRPNaFSDgDSalofgelsesssviefdrtkdapvvdapvdlitsnealsvvdpfefaelkrprfsaqalidrggpladvhakiknrvyeccloacepgsratpatrewldkomdr T.V NVDC-NM1-2011 NVDC-NM2 NVDC-NM3 NVDC-F.T BJEU06-1 NMEU09-1 EuroPRRSV 01CB1 SD01-08 KNU-07 HKEU16 Lena ES7 SISQRLMTWVFEVFSHLPAFMLTLFSPRGSMAPGDW-LFAGVVLLALLLCRSYPILGCLPLLGVFSGSLRRVRLGVFGSWMAFAVFLFSTPSNPVGSSCDHDSPECHAELLALEQRQLWE
 LV
 STSGRLMTWOFEVESUBAPHILTLFSPRGSMAPGOV/LEAGVVLLALLCRSVPILGCLPLLGVFGSLRWRFAGVFLFSTPSNPVGSSCDHDSPECHAELLALEQQQLWE

 NVDC-NN2
 T.C.
 IY.
 A.
 H.
 P.
 VT.
 T.
 F.
 F.

 NVDC-NN3
 T.C.
 IY.
 MA
 H.
 P.
 VT.
 TS.
 NVD.

 NVDC-NN3
 T.C.
 IY.
 MA
 H.
 S.
 V.
 V.
 TS.

 NVDC-NN3
 T.C.
 IY.
 M.
 H.
 S.
 V.
 V.
 TS.

 NVDC-SN3
 T.C.
 IY.
 H.
 S.
 V.
 V.
 TS.

 NVDC-SN3
 T.C.
 IY.
 H.
 S.
 V.
 V.
 TS.

 DSDEU06-1
 F.
 Y.
 A.
 H.
 S.
 V.
 V.
 TD.

 BJEEU06-1
 T.Y. MR. IY.
 P.
 H.
 N.
 TD.
 N.

 BJEEU06-1
 T.Y. MR. IY.
 P.
 H.
 N.
 TD.
 Q.

 SDG10-08
 AG.
 Y.
 LV 861 PVRGLVVGPSGLLCVILGKLLG LV FVRGLVV6PSGLLCVIL6KLG NVDC-NN2 .S. NVDC-NN2 .S. NVDC-FN3 .S. BVEU06-1 NEEU09-1 EuroPRASV 01CB1 ... SD01-08 ... RNU-07 ... HKEU16 ... Lena .S...F..G. LV

Table 2 Structural proteinamino acid identity of fourisolates with LV strain

Protein name	% of identity to LV strain						
	NVDC-NM1-2011 (%)	NVDC-NM2 (%)	NVDC-NM3 (%)	NVDC-FJ (%)			
ORF2a/GP2	94.4	91.6	91.6	91.6			
ORF2b/E	91.7	87.5	87.5	87.5			
ORF3/GP3	86.4	85.2	85.2	85.2			
ORF4/GP4	87.4	90.3	90.3	91.4			
ORF5/GP5	90.8	83.7	83.7	83.7			
ORF5a	95.3	90.7	90.7	90.7			
ORF6/M	96.0	93.6	93.6	91.9			
ORF7/N	92.2	94.5	96.1	96.1			

previous studies, the GP3 hypervariable region of four isolates contained multiple deletions and mutations. Continuous deletion of 8 aa (at positions 240–247 of GP3 or 60–67 of GP4) was observed in the hypervariable region of NVDC-NM2, NVDC-NM3, and NVDC-FJ isolates (Fig. 3a, b). In addition, 2 aa mutations (N27-T27 and S29-N29) were detected in one of seven potential N-glycosylation sites in GP3, indicated by the red boxes in Fig. 3a. In contrast, only 1 aa deletion (at position 245 of GP3 and position 65 of GP4) was detected in the GP3 hypervariable region of NVDC-NM1-2011 and no glycosylation site changes were found (Fig. 3a, b).

GP5, the most variable envelope glycoprotein, was encoded by ORF5 and comprised 201 amino acids in PRRSV-Type 1 viruses. This protein binds to M protein to form a disulfide-linked heterodimer that contains multiple primary neutralization sites [30, 31]. Previous studies indicated that the hypervariable region of GP5 includes the signal peptide sequence (at residues 1-33) and two ectodomains (at residues 33-67 and 89-109). Variation in these regions tends to affect the number of potential N-glycosylation sites and is expected to confer sensitivity to selective pressure from the porcine antibody response [32, 33]. In this study, we detected 11 amino acid substitutions within the ORF5 hypervariable region of NVDC-NM1-2011 (2 aa substitutions were found in the signal peptide sequence and 9 aa substitutions in two ectodomains) when compared to the LV PRRSV strain. 1 aa substitution (at residue 189) was found in ES13 (Fig. 4). In contrast, 17 amino acid substitutions were observed within the ORF5 hypervariable region of the 3 other isolates including substitution of 6 aa in the signal peptide sequence and 11 aa in two ectodomains. Notably, an additional N-glycosylation site at position 37 was detected in all four isolates (Fig. 4).

Phylogenetic analysis of 4 PRRSV-Type 1 isolates and other PRRS viruses

To establish genetic relationships between the isolated strains and previously characterized strains, phylogenetic

analysis was performed on the full-length genomic sequences of the four isolates, 22 PRRSV strains including 5 PRRSV-Type 2 viral strains and 13 PRRSV-Type 1 viral strains in the GenBank database (Suppl. Table). The four isolates could be divided into different branches within the PRRSV-Type 1 Subtype 1 that is predominant in Europe [34]. NVDC-NM2, NVDC-NM3, and NVDC-FJ were closely related within the same branch, and NVDC-NM1-2011 fall into separate branch within Subtype 1 (Fig. 5). In addition, further phylogenetic analysis based on ORF5 and ORF7 nucleotide sequences also indicated that these isolates could be divided into two branches within the PRRSV-Type 1 Subtype 1 (data not shown).

Discussion

PRRS has now emerged as one of the most prevalent swine diseases in China, particularly after the unparalleled outbreaks of HP-PRRSV since 2006 [35, 36]. While PRRSV-Type 2 strains have previously been detected most often in China, the PRRSV-Type 1 has also been detected in China since 2011 [17]. In this study, nation-wide PRRSV surveillance of serum samples collected from 80 breeding swine farms provided the opportunity to comprehensively study the prevalence of PRRSV-Type 1 virus in China.

Four PRRSV-Type 1 viruses were successfully isolated and were subjected to genomic sequencing. Genomic sequence analysis confirmed the diversity of the PRRSV-Type 1 virus in China. In comparison to the LV strain, the complete genomic sequences of four isolates contained mutations within the nonstructural and structural proteins. Nsp1B, Nsp2, ORF3, ORF4, and ORF5 exhibited the highest level of variation. PRRSV-Type 1 viruses were previously reported to contain different deletions within Nsp2 or ORF3 hypervariable regions than the LV strain [29–33]. In this study, all four isolates also contained deletions in these two hypervariable regions.

NSP2, the largest PRRSV protein, is crucial for the proteolytic processing of proteins during virus replication

Δ			
1	1 27 29		133
TV	MAHOCADEHEEL COELCYL VHSAL ASASSETL CEWEDLAHONTSEELTINYTTCMPCSTSOA	ADODI EDCOMMUCKICHODOCEEDDHDEI I MSI DSCYDNI KI	FOUND A FI SESVAAOFHDET FOTOWSP
NVDC_NM1_2011	D V FT T K L D	M D M S	STIAWERFESTSTRAGENPEEPOIG
NVDC-NM2	C L S CGS T NH L	T TS RA	
NVDC-NM3	C I S CGS T NH I	T TS DA	
NVDC-FJ	C L S CGS T NH L	I TS SL	,
BJEU06-1		SH V	
NMELIO9-1	P CT. VSEPS N P		,
FuroPRESV	F. V. P.	T	
01CB	D D		
SD01-08	С <u>а</u> т.	P	
KNU-07	D. TC. I. S. F.BG. S.N.	K. HS. TS. S. T	
HKFU16		H R AT T	т
Lena	C. SC. Y. L.F. VG. TCG. N. A. B. L. BR.	.O.S	
bena			
1	34	2	240 247 266
LV	VFVDKRHQFICAEHDGHNSTVSTGHNISALYAAYYHHQIDGGNWFHLEWLRPLFSSWLVINIS	WFLRRSPVSPVSRRIYQILRPTRPRLPVSWSFRTSIVSDLT(SOORK-RKFPSESRPNVVKPSVLPSTSR
NVDC-NM1-2011			RPIP.QLGRS.AAM
NVDC-NM2	VVF	HAP.PG	ROPANHLSAFL
NVDC-NM3	VVFF.	HAP.PG	RQPANHLSAFL
NVDC-FJ	VVF	HA	RQPANHLSAFL
BJEU06-1	Q	A	YPANHLAF
NMEU09-1	F	AL.PGF.	D.A.HLLAF
EuroPRRSV	W	QMI	RGGAANI
01CB	PP		
SD01-08	G.LLEV	PG	RPVPAF.N
KNU-07	VLINSVFV.	AA	ASA. IRNSRAAPH
HKEU16	QYHI.AVVVFF	P.PG	H.A.HLARAFL
Lena	H	HAKPSTAF.I.P	RI.TS.PP*.DLA.LL.PQ
В	1 60	67	120
LV	MAAATLFFLAGAQHIMVSEAFACKPCFSTHLSDIETNTTAAAGFMVLQDINCFRPHGVSAAQ	EK-ISFGKSSQCREAVGTPQYITITANVTDESYLYNADLLML	SACLFYASEMSEKGFK
NVDC-NM1-2011	ILVV	STFGTIVK	
NVDC-NM2	TIVSLKKLLT.AEATR		.T
NVDC-NM3	TIVSLKKLT.AEATR		.T
NVDC-FJ	T T V T T T T T T T T T T T T T T T T T	P	
BJEU06-1	U T VC T NV T TAL CID		
NMEU09-1	T T T T T T T T T T T T T T T T T T T		
LUFOPRESV	λ τ	_	u
SD01-08	AFLV K NSFAT(CO-VPSP V	
SD01-00	TLU DI K DN KEIO DG TT (
NINO-07	VILVSIV NK LTATIC	Р т	
LODO	ST V F K V DIHONNS	PPATTM R T V S DA H	
Lena			
12	21 1	84	
		1	
LV	VIFGNVSGVVSACVNFTDYVAHVTQHTQQHHLVIDHIRLLHFLTPSAMRWATTIACLFAILLA	AI	
NVDC-NM1-2011	N		
NVDC-NM2	·····N······		
NVDC-NM3	N		
NVDC-FJ	N		
BJEU06-1	N		
NMEU09-1	A	•	
EUROPERSV	T		
UILB			

Fig. 3 Amino acid variants in ORF3 and ORF4 of four isolates and other PRRSV-Type 1 viruses. **a** The 1-aa deletion at position 245 of ORF3 in NVDC-NM1-2011 and the 8-aa deletion at position 240–247 in ORF3 in the other three isolates were indicated by a *solid box*.

.v.....v......v....s..t.

.....A......A.....

SD01-08

KNU-07

HKEU16

Lena

Seven potential N-glycosylation sites in ORF3 were indicated by *red boxes*. **b** The 1-aa deletion at position 65 of ORF4 in NVDC-NM1-2011 and the 8-aa deletion at position 60–67 in ORF4 of the other 3 isolates were indicated by a *solid box* (Color figure online)

and modulation of immune responses [29, 30]. This protein possesses a putative conserved cysteine protease domain and contains six B-cell epitopes. ES2 is located in the putative cysteine protease domain, a domain important for viral survival and modulation of immune responses [28, 29]. In this study, ES2 was well conserved in the four isolates, which is consistent with earlier findings. The most variable region of NSP2 in these four isolates was located between the ES3 and ES4. Four aa deletions were detected in ES3 and 1 aa deletion was detected in ES4. Whether such deletions influence the virulence of PRRSV strains remains to be investigated.

The greatest amino acid variability in these isolates was detected in GP3 and GP5 in accordance with previous studies [31–33, 37, 38]. GP3 contains a hypervariable region located in the carboxyl-terminal end overlapping with ORF4. Previous studies indicated that this region may be subject to more rapid changes than other regions during immune selective pressure [29, 30, 38]. Moreover, the ES12 of GP4 is also located in this overlap region, and may

	1	24 33	67	89 10
LV	MRCSHKLGRFLTPHSCFWWLFLL	CTGLSWSF DGNGDS	STYQYIYNLTICELNGTDWLSSHFGWAVE	rfvlypvathilslgflttshffdalglgavsta
NVDC-NM1-2011	EH	N.	EY	VVT
NVDC-NM2	R.V.SS	.I.SNC	5. <mark>DH.T</mark>	IVT
NVDC-NM3	IR.V.SS	.I.SNC	5. <mark></mark>	IILTVT
NVDC-FJ	R.V.SS	.I.SNC	5. <mark></mark>	IILTVT
BJEU06-1	.KEH.SF.	T.		F
NMEU09-1	I	N.		vvLTVT
EuroPRRSV	YS.ILSF	N	1GD	v
01CB1				v
SD01-08	.KHS	N	1GE	v
KNU-07	I		ATP.V	
HKEU16		.ICN	D	AT
Lena	RTQPS.HYL	N	EVND	5FVAV.
	10 2 10 9			189 ES13 20
LV	102 109	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK	189 ES13 20 AEVDGNLVTIKHVVLEGVKZOPLTRTSAEQWEA
LV NVDC-NM1-2011	10 2 10 9 GFVGGRYVLCSVYGACAFAAFVC	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK	189 ES13 20 AEVDGNLVTIKHVVLEGVKAOPLTRTSAEQWEA
LV NVDC-NM1-2011 NVDC-NM2	102 109 GFVGGRYVLCSVYGACAFAAFVC L.N.F. S.IL. 	FVIRAAKNCMACRY	ARTRFINFIVDDRGRVHRWKSPIVVEKLGK. I	189 ES13 20 AEVDGNLVTIKHVVLEGVKAOPLTRTSAEQWEA D
LV NVDC-NM1-2011 NVDC-NM2 NVDC-NM3	102 109 GFVGGRYVLCSVYGACAFAAFVC L.N.F.S.IL. SRSVL. SRSVL	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK II	189 ES13 20 AEVDGNLVTIKHVVLEGVKACPLTRTSAEQWEA DRR IGSDFR
LV NVDC-NM1-2011 NVDC-NM2 NVDC-NM3 NVDC-FJ	102 109 GFVGGRYVLCSVYGACAFAAFVC .L.N.F.S.IL. SR.S.V.L. SR.S.V.L. SR.S.V.L.	FVIRAAKNCMACRY. T T T	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK I	189 ES13 20 AEVDGNLVTIKHVVLEGVKZ PLTRTSAEQWEA D. IGSDFR. .IGSDFR. .IGSDFR.
LV NVDC-NM1-2011 NVDC-NM2 NVDC-NM3 NVDC-FJ BJEU06-1	102 109 GFVGGRYVLCSVYGACAFAAFVC .L.N.F. S.IL. SRSVL. SRSVL. SRSVL. SRSVL.	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK I	189 ES13 20 AEVDGNLVTIKHVVLEGVK2 PLTRTSAEQWEA R.
LV NVDC-NM1-2011 NVDC-NM2 NVDC-NM3 NVDC-FJ BJEU06-1 NMEU09-1	102 109 GFVGGRYVLCSVYGACAFAAFVC L.N.F. SRSVL. SRSVL. SRSVL. SRSVL. SRSVL. SRSVL.	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK IM. IM. IM. IM. II. II.	189 ES13 20 AEVDGNLVTIKHVVLEGVKZ PLTRTSAEQWEA DR IGSDF.R IGSDF.R G.D IGSDF.R
LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV	10.2 10.9 GFVGGRYVLCSVYGACAFAAFVC	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK IM. IM. IM. IM. IM. IM. G.	189 ES13 20 AEVDGNLVTIKHVVLEGVKZ PLTRTSAEQWEA DR IGSDF.R IGSDF.R G.D IGSDF.R JGSDF.R JGSDF.
LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV 01CB1	10.2 10.9 GFVGGRYVLCSVYGACAFAAFVC L.N.F. SRSVL. LDRSL.L. NSV.	FVIRAAKNCMACRY	ARTRFINFIVDDRGRVHRWKSPIVVEKLGK IM. IM. IM. IM. II. IM. G.	189 ES13 20 AEVDGNLVTIKHVVLEGVKZ PLTRTSAEQWEA DR IGSDF.R IGSDF.R IGSDF.R JGSDF. D JL.S.
LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV 01CB1 SD01-08'	102 109 GFVGGRYVLCSVYGACAFAAFVC .L.N.F.S.IL. .SR.S.V.L. .SR.S.V.L. .LDR.S.V.L. .LDR.S.L.L. .IDR.S.V.L. .L. .S.V.L. 	FVIRAAKNCMACRY	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK I I I I I G. 	189 ES13 20 AEVDGNLVTIKHVVLEGVRJ PLTRTSAEQWEA R R D. R. R R R IGSD. F. R R R IGSD. F. R R R IGSD. F. R R R IGSD. F. R R R IGSD. F. R R IGSD. F. R R R R R IG. IG. R
LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV 01CB1 SD01-08' KNU-07	102 109 GFVGGRYVLCSVYGACAFAAFVC .L.N.F.S.IL. .SR.S.V.LL .SR.S.V.LL .LDR.S.V.LL .LDR.S.LLL .LDR.S.I.LL .L. .L. .L. .L. 	FVIRAAKNCMACRY.	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK I I I I I M. I G. G. I.V.	189 ES13 20 AEVDGNLVTIKHVVLEGVKA PLTRTSAEQWEA PLTRTSAEQWEA D. R. IGSD. F. R. IGSD. F. R. IGSD. IGSD. IGSD. F. R. IGSD. IGSD.
LV NVDC-NM1-2011 NVDC-NM2 NVDC-FJ BJEU06-1 NMEU09-1 EuroPRRSV 01CB1 SD01-08' KNU-07 HKEU16	10.2 10.9 GFVGGRYVLCSVYGACAFAAFVC	FVIRAAKNCMACRY. T. 	ARTRFTNFIVDDRGRVHRWKSPIVVEKLGK I	189 ES13 20 AEVDGNLVTIKHVVLEGVKA PLTRTSAEQWEA PLTRTSAEQWEA R. IGSD F. R. IGSD F. R. IGSD F. R. IGSD F. R.

Fig. 4 Amino acid variants in ORF5 of four isolates, compared with other PRRSV-Type 1 viruses. The functional domains were reported according to Stadejek et al. [33]. The putative signal sequences (*dotted line boxes*) and hypervariable domains (*solid boxes*) were

Fig. 5 Phylogenetic analysis of four isolates with other PRRSV-Type 1 strains based on the complete genomic sequence. Alignments were analyzed using the neighbor-joining method with the Kimura 2-parameter algorithm in MEGA4.1. Each isolate was indicated by virus name, GenBank accession no., and country of origin. The four isolates were indicated with dark triangle symbols. The reliability of the tree was assessed by bootstrap analysis with 1000 replications

indicated. Potential N-glycosylation sites were shown in the *red boxes*. The mutation at position 37 (D37 \rightarrow N37) in all four isolates as shown by the *red box*. One mutation observed at ES13 of NVDC-NM1-2011 was indicated by the *blue box* (Color figure online)



act as a decoy epitope and play an important role in delaying the induction of PRRSV-neutralizing antibodies [17, 29, 38, 39]. In this study, the 8-aa deletion in NVDC-NM2, NVDC-NM3, and NVDC-FJ and 1 aa deletion of

NVDC-NM1-2011 was located in ES12, which led to the disruption of the ES12 conformation.

GP5 is the most variable PRRSV structural protein. Amino acid variations in GP5 were mainly observed in the hypervariable region of the ectodomain, which possesses many potential N-glycosylation sites. These potential N-glycosylation sites are involved in viral immune evasion and minimize the virus-neutralizing antibody response [17, 29, 30, 32]. All four strains isolated in this study differed from LV at position 37 (D37-N37) and NVDC-NM1-2011 contained a 1 aa mutation in ES13. Whether the increase in glycosylation sites or amino acid mutation in GP3 and GP5 immune-dominant epitopes are related to the sensitivity of PRRSV to neutralization remains unknown.

To gain further insight into the genetic relationships between these isolates and other PRRSV-Type 1 isolates, phylogenetic analysis was performed on the whole genome of the four isolates, in addition to 22 PRRSV strains including 5 PRRSV-Type 2 viruses, and 13 PRRSV-Type 1 prototypic strains. We also performed phylogenetic analysis of the ORF5 of 100 strains and the ORF7 of 96 strains listed in the GenBank database. The phylogenetic trees revealed that all four isolates belonged to PRRSV-Type 1 Subtype 1, and could be further divided into two branches. NVDC-NM1-2011 belongs to one branch, while the other three strains were closely related within the other branch. Remarkably, NVDC-NM1-2011, NVDC-NM2, and NVDC-NM3 isolated from different breeding swine farms in the same province were divided into different branches. These results suggested that there was no clear geographical link between the four isolates, and suggested that independent EU PRRSV evolution is currently occurring in Chinese swine herds.

In summary, these results indicate that EU genotype PRRSV underwent gradual variation and has accumulated genomic changes since its introduction to Mainland China.

Acknowledgments This work was supported by Grants from the Swine Industry Technology System Building of Beijing (GWZJ-2009-05), the National Basic Research Program of China (2008FY130100-2), and the Scientific Achievement Transformation Program (2009GB23260435). We thank Dr. Xiangdong Li at National Research Center for Veterinary Medicine, Cuiwei Road, High-Tech. District, Luoyang, Henan Province, China for providing revision of the grammar, and readability of the manuscript.

References

- G. Wensvoort, C. Terpstra, J.M. Pol, E.A. terLaak, M. Bloemraad, E.P. deKluyver, C. Kragten, L. van Buiten, A. denBesten, F. Wagenaar, J.M. Broekhuijsen, P.L.J.M. Moonen, T. Zetstra, E.A. de Boer, H.J. Tibben, M.F. de Jong, P. van't Veld, G.J.R. Greenland, J.A. vanGennep, M.Th. Voets, J.H.M. Verheijden, J. Braamskamp, Vet. Q. 13(3), 121–130 (1991)
- R. Allende, T.L. Lewis, Z. Lu, D.L. Rock, G.F. Kutish, A. Ali, A.R. Doster, F.A. Osorio, J. Gen. Virol. 80, 307–315 (1999)
- J.J. Meulenberg, M.M. Hulst, E.J. de Meijer, P.L. Moonen, A. den Besten, E.P. de Kluyver, G. Wensvoort, R.J. Moormann, Virology 192, 62–72 (1993)

- J.J. Meulenberg, A. Petersen-den Besten, E.P. De Kluyver, R.J. Moormann, W.M. Schaaper, G. Wensvoort, Virology 206, 155–163 (1995)
- A.E. Firth, J.C. Zevenhoven-Dobbe, N.M. Wills, Y.Y. Go, U.B. Balasuriya, J.F. Atkins, E.J. Snijder, C.C. Posthuma, J. Gen. Virol. 92(Pt5), 1097–1106 (2011)
- C.R. Johnson, T.F. Griggs, J. Gnanandarajah, M.P. Murtaugh, J. Gen. Virol. 92, 1107–1116 (2011)
- 7. E.J. Snijder, J.J. Meulenberg, J. Gen. Virol. 79, 961-979 (1998)
- M.B. Oleksiewicz, A. Bøtner, K.G. Madsen, T. Storgaard, Vet. Microbiol. 64(1), 7–22 (1998)
- L. Zhou, S. Chen, J. Zhang, J. Zeng, X. Guo, X. Ge, D. Zhang, H. Yang, Virus Res. 145(1), 97–105 (2009)
- J.E. Collins, D.A. Benfield, W.T. Christianson, L. Harris, J.C. Hennings, D.P. Shaw, S.M. Goyal, S. McCullough, R.B. Morrison, H.S. Joo, D. Gorcyca, D. Chladek, J. Vet. Diagn. Invest. 4, 117–126 (1992)
- K.G. Madsen, C.M. Hansen, E.S. Madsen, B. Strandbygaard, A. Bøtner, K.J. Sørensen, Arch. Virol. 143(9), 1683–1700 (1998)
- C. Egli, B.L. Liu, M.A. Hofmann, J. Virol. Methods 98(1), 63–75 (2001)
- B. Guo, Z. Chen, W. Liu, Y. Cui, Chin. J. Anim. Poult. Infect. Dis. 17, 1–4 (1996)
- A. Amonsin, R. Kedkovid, S. Puranaveja, P. Wongyanin, S. Suradhat, R. Thanawongnuwech, Virol. J. 6, 143 (2009)
- G. Balka, A. Hornyak, A. Balint, I. Kiss, S. Kecskemeti, T. Bakonyi, M. Rusvai, Vet. Microbiol. 127, 128–135 (2008)
- A. Bøtner, B. Strandbygaard, K.J. Sørensen, P. Have, K.G. Madsen, E.S. Madsen, S. Alexandersen, Vet. Rec. 141, 497–499 (1997)
- N.H. Chen, Z. Cao, X.L. Yu, X.Y. Deng, T. Zhao, L. Wang, Q. Liu, X. Li, K. Tian, J. Gen. Virol. 92, 880–892 (2011)
- S.B. Kleiboeker, S.K. Schommer, S.M. Lee, S. Watkins, W. Chittick, D.J. Polson, Vet. Diagn. Invest. 17, 165–170 (2005)
- H.S. Kim, J. Kwang, I.J. Yoon, H.S. Joo, M.L. Frey, Arch. Virol. 133, 477–483 (1993)
- D. Zeman, R. Neiger, M. Yaeger, E. Nelson, D. Benfield, P. Leslie-Steen, J. Thomson, D. Miskimins, R. Daly, M. Minehart, J. Vet. Diagn. Invest. 5(4), 522–528 (1993)
- 21. G. Lu, E.N. Moriyama, Brief Bioinform. 5(4), 378-388 (2004)
- K. Tamura, J. Dudley, M. Nei, S. Kumar, Mol. Biol. Evol. 24, 1596–1599 (2007)
- 23. V. Kapur, M.R. Elam, T.M. Pawlovich, M. Murtaugh, J. Gen. Virol. 77, 1271–1276 (1996)
- M.B. Oleksiewicz, A. Bøtner, J. Nielsen, T. Storgaard, Arch. Virol. 144, 981–987 (1999)
- G. van Marle, J.C. Dobbe, A.P. Gultyaev, W. Luytjes, W.J. Spaan, E.J. Snijder, Proc. Natl. Acad. Sci. USA 96(21), 12056–12061 (1999)
- Y. Fang, D.Y. Kim, S. Ropp, P. Steen, J. Christopher-Hennings, E.A. Nelson, R.R. Rowland, Virus Res. 100, 229–235 (2004)
- M. de Lima, A.K. Pattnaik, E.F. Flores, F.A. Osorio, Virology 353, 410–421 (2006)
- M.B. Oleksiewicz, A. Bøtner, P. Toft, P. Normann, T. Storgaard, J. Virol. **75**, 3277–3290 (2001)
- S.L. Ropp, C.E. Wees, Y. Fang, E.A. Nelson, K.D. Rossow, M. Bien, B. Arndt, S. Preszler, P. Steen, J. Christopher-Hennings, J.E. Collins, D.A. Benfield, K.S. Faaberg, J. Virol. 78(7), 3684–3703 (2004)
- S. Dea, C.A. Gagnon, H. Mardassi, B. Pirzadeh, D. Rogan, Arch. Virol. 145, 659–688 (2000)
- M.H. Verheije, T.J. Welting, H.T. Jansen, P.J. Rottier, J.J. Meulenberg, Virology 30, 364–373 (2002)
- B. Pirzadeh, C.A. Gagnon, S. Dea, Can. J. Vet. Res. 62, 170–177 (1998)

- T. Stadejek, A. Stankevicius, T. Storgaard, M.B. Oleksiewicz, S. Belak, T.W. Drew, Z. Pejsak, J. Gen. Virol. 83, 1861–1873 (2002)
- T. Stadejek, M.B. Oleksiewicz, A.V. Scherbakov, A.M. Timina, J.S. Krabbe, K. Chabros, D. Potapchuk, Arch. Virol. 153, 1479–1488 (2008)
- 35. K.G. Tian, X.L. Yu, T.Z. Zhao, Y.J. Feng, Z. Cao, C. Wang, Y. Hu, X. Chen, D. Hu, X. Tian, D. Liu, S. Zhang, X. Deng, Y. Ding, L. Yang, Y. Zhang, H. Xiao, M. Qiao, B. Wang, L. Hou, X. Wang, X. Yang, L. Kang, M. Sun, P. Jin, S. Wang, Y. Kitamura, J. Yan, G.F. Gao, PLoS One 2(6), e526 (2007)
- T.Q. An, Z.J. Tian, C.L. Leng, J.M. Peng, G.Z. Tong, Emerg. Infect. Dis. 17(9), 1782–1784 (2011)
- R. Forsberg, M.B. Oleksiewicz, A.M.K. Petersen, J. Hein, A. Bøtner, T. Storgaard, Virology 289, 174–179 (2001)
- M.B. Oleksiewicz, A. Bøtner, P. Toft, T. Grubbe, J. Nielsen, S. Kamstrup, T. Storgaard, Virology 267, 135–140 (2000)
- T.W. Drew, J.P. Lowings, F. Yapp, Vet. Microbiol. 55, 209–221 (1997)